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Improving approaches for hematopoietic stem cell (HSC) and hematopoietic progenitor cell 
(HPC) mobilization is clinically important because increased numbers of these cells are 
needed for enhanced transplantation. Chemokine stromal cell derived factor-1 (also known 
as CXCL12) is believed to be involved in retention of HSCs and HPCs in bone marrow. 
AMD3100, a selective antagonist of CXCL12 that binds to its receptor, CXCR4, was evaluated 
in murine and human systems for mobilizing capacity, alone and in combination with 
granulocyte colony-stimulating factor (G-CSF). AMD3100 induced rapid mobilization of 
mouse and human HPCs and synergistically augmented G-CSF–induced mobilization of HPCs. 
AMD3100 also mobilized murine long-term repopulating (LTR) cells that engrafted primary 
and secondary lethally-irradiated mice, and human CD34
 
 
 
 cells that can repopulate 
nonobese diabetic-severe combined immunodeficiency (SCID) mice. AMD3100 synergized 
with G-CSF to mobilize murine LTR cells and human SCID repopulating cells (SRCs). Human 
CD34
 
 
 
 cells isolated after treatment with G-CSF plus AMD3100 expressed a phenotype that 
was characteristic of highly engrafting mouse HSCs. Synergy of AMD3100 and G-CSF in 
mobilization was due to enhanced numbers and perhaps other characteristics of the mobilized 
cells. These results support the hypothesis that the CXCL12-CXCR4 axis is involved in 
marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 
for HSC mobilization.
 
Hematopoietic stem cells (HSCs) give rise to
blood-forming cells through intermediates
that are termed hematopoietic progenitor cells
(HPCs), including common myeloid (e.g.,
CFU–granulocyte erythroid macrophage, mega-
karyocyte
 
 
 
[GEMM]/CFU-Mix), lymphoid pro-
genitors, and more lineage-restricted progeni-
tors (e.g., CFU–granulocyte macrophage [GM],
CFU-G, CFU-M, burst-forming unit–eryth-
roid
 
 
 
[BFU-E]) (1–3). Movement of HSCs/
HPCs between marrow (their main site of
production) and blood is a physiological pro-
cess (4, 5); few HSCs/HPCs circulate in blood.
Increased concentrations of HSCs/HPCs are
present in cord blood (6); postbirth, these cells
can be mobilized in increased numbers to the
blood (7–9).
Granulocyte colony-stimulating factor (G-
CSF) is the “gold-standard” to mobilize HSCs/
HPCs for transplantation (7, 8). However,
broad interindividual variability exists in this
mobilization (10); variability also is seen in dif-
ferent mouse strains (11, 12). Poor HSC/HPC
mobilization in response to G-CSF is apparent
in heavily-treated patients who have cancer
and genetic disorders, such as Fanconi’s ane-
mia (7, 8, 13). In part, this may reflect a de-
creased pool of HSCs and/or HPCs. Other
agents have been used to mobilize and en-
hance G-CSF–induced mobilization (7). One
mobilizing cytokine, stem cell factor, was with-
drawn from clinical development in the United
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States because of toxicity concerns (14); hence, the search
for other agents to mobilize HSCs/HPCs, alone and with
G-CSF.
SDF-1/CXCL12 and its receptor, CXCR4, are impli-
cated in chemotaxis (15–18), homing (19–21), survival/
antiapoptosis of HSCs/HPCs (22, 23). SDF-1/CXCL12-
CXCR4 may be involved in retention of HSCs and HPCs
within the marrow (16, 20); this suggests that antagonizing
interactions of marrow produced SDF-1/CXCL12 with
CXCR4 expressed on HSCs and HPCs, or changing the
SDF-1/CXCL12 gradient between marrow and blood might
be useful as a HSC/HPC mobilizing strategy (24–27). How-
ever, the role of altered SDF-1/CXCL12 gradients in mobi-
lization and on functional CXCR4 expression in G-CSF
mobilized cells has not been established definitively, and
none of these preclinical (24–27) efforts has been adapted for
clinical HSC/HPC mobilization. As a further proof of prin-
ciple that antagonizing SDF-1/CXCL12-CXCR4 interac-
Figure 1. Time and dose response effects of AMD3100 as a mobi-
lizer of HPC (CFU-GM, BFU-E and CFU-GEMM) to the blood of mice. 
(A) Time course of mobilization in response to a single s.c. injection of 
5 mg/kg AMD3100 into C3H/HeJ mice; results are for one full experiment 
(5 mice/group and time 0 control numbers of CFU-GM, BFU-E, and 
CFU-GEMM per ml of blood were 78   18, 17   2, and 10   2, respectively). 
(B) Dose response analysis at 1 h post s.c. injections of 0.625, 1.25, 2.5, 5.0, 
or 10 mg/kg AMD3100 into C3H/HeJ mice; results are average of 7 mice/
group from a total of two separate experiments. (C) Influence of multiple 
injections of 5 mg/kg AMD3100 or saline given on day 1; days 1 and 2; or 
days 1, 2, and 3 given 24 h apart, and analyzed 1 h after the last injection 
into C3H/HeJ mice; results are average of 14 mice for control group for 
different timed saline injections and 8 mice for each test group from a total 
of two complete experiments. *P   0.05; **P   0.01; ***P   0.001. 
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tions results in mobilization of HSCs/HPCs and that this an-
tagonism can result in clinically useful effects, we evaluated
the capacity of AMD3100—a bicyclam that specifically and
reversibly blocks SDF-1/CXCL12 binding to, and signaling
through, CXCR4 (28–30)—to mobilize HSCs and HPCs in
mice and man alone, and in combination with G-CSF. We
and others reported that AMD3100 mobilizes CD34
 
 
 
 cells
and HPCs in man (31–33) and more recently reported that
AMD3100 enhances G-CSF–induced mobilization of CD34
 
 
 
cells in man (34). However, HSCs make up an extremely
small percentage of the CD34
 
 
 
 population, and it is not yet
clear whether AMD3100 mobilizes functionally effective
HSCs, alone and in combination with G-CSF in mouse
and man.
 
RESULTS
AMD3100 effects on murine HPCs, without and with G-CSF
 
We evaluated the effects of AMD3100 on mobilization of
CFU-GM, BFU-E, and CFU-GEMM to the blood of
C3H/HeJ mice (Fig. 1, A–C). Although no endotoxin was
Figure 2. Comparative AMD3100 enhancement of G-CSF–induced 
mobilization of CFU-GM, BFU-E, and CFU-GEMM in: (A) 2 d G-CSF: 
C57Bl/6, C3H/HeJ, DBA/2, (B) 4 d G-CSF: C57Bl/6, and (C) 4 d of 
G-CSF: Fancc /  and  /  mice. The results shown in A are an average 
from a total of three experiments of 15 C57Bl/6, 15 DBA/2, and 11 C3H/HeJ 
mice. Results in B are for one experiment of 5 mice/group. Results shown 
in C are the averages of 15 wild-type and 8 Fancc    mice per group aver-
aged from a total of two experiments. For parts A–C, all experimental 
points within a group are at least P   0.001 compared with the control 
for the specific progenitor cell of each mouse strain. 
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detected in the samples of AMD3100 that were used, we
chose C3H/HeJ mice as our first test mouse strain because
these mice are relatively insensitive to endotoxin. Using a
dose of 5 mg/kg AMD3100 s.c., peak mobilization of HPC
occurred 1 h postinjection (Fig. 1 A). Data from various
time points were reproduced in two or three additional ex-
periments in terms of relative peak changes with control col-
ony numbers of: 74–290 CFU-GM, 17–49 BFU-E, and 10–
26 CFU-GEMM. Maximal mobilization of HPC at 1 h was
noted with 2.5–10.0 mg/kg AMD3100 s.c. (Fig. 1 B). Ster-
ile pyrogen-free saline (control medium) or AMD3100 (5
mg/kg s.c.) was injected on day 1, days 1 and 2, or days 1–3
and the blood of these mice was evaluated 1 h after injection
of control medium or AMD3100 (Fig. 1 C). HPC mobiliza-
tion was similar each day (no significant difference between
the three AMD3100 groups) which suggested that within
this timing period, the HPC-mobilizing capacity of AMD3100
is not desensitized. AMD3100 also was a potent mobilizer of
HPCs in other strains of mice, as noted below.
Broad interindividual variability exists in mobilization of
HSCs/HPCs in different strains of mice (11, 12), and man (7,
8, 10). In some patients, G-CSF is a poor mobilizer (7, 8, 13).
Thus, we evaluated the mobilizing capability of AMD3100 in
comparison with G-CSF, and in combination with G-CSF,
in strains of mice that were reported to differ in responsive-
ness to G-CSF. C57Bl/6 mice respond poorly to mobilizing
effects of G-CSF compared with DBA/2 mice (11, 12). Mice
were injected s.c. with control medium (sterile pyrogen-free
saline) or 2.5 
 
 
 
g G-CSF per mouse, twice a day for 2 d (35)
and 18 h after the last control injections were injected s.c.
with control medium or 5 mg/kg AMD3100. Mice were
bled 1 h later, and numbers of HPCs (Fig. 2 A) were calcu-
lated per ml of blood. HPC from C57Bl/6 and C3H/HeJ
mice responded less-well to the mobilizing capacity of
G-CSF than DBA/2 mice, consistent with studies of others
(11, 12). AMD3100 mobilized CFU-GM and a single injec-
tion of AMD3100 synergized with 2 d of G-CSF to enhance
mobilization of HPC, although maximum mobilization with
AMD3100 plus G-CSF was significantly greater in DBA/2,
compared with either C57/Bl/6 or C3H/HeJ mice (P 
 
 
 
0.001) (Fig. 2 A). Synergism in mobilization of CFU-GM
was also seen in C57Bl/6 mice when G-CSF was adminis-
tered to mice twice a day for 4, instead of 4, d before injec-
tion of AMD3100 (Fig. 2 B). With 4 d of G-CSF, the effects
of AMD3100 plus G-CSF were additive to slightly greater
than additive on mobilization of BFU-E and CFU-GEMM.
Many patients who have Fanconi’s anemia are poor re-
sponders to HPC mobilization with G-CSF (13). G-CSF
was a less effective mobilizer of HPC in Fanconi’s anemia
complementation C group gene (Fancc)
 
 
 
/
 
 
 
 compared with
Fancc
 
 
 
/
 
 
 
 WT mice (Fig. 2 C; in these studies, G-CSF was
administered twice a day for 4 d). AMD3100 as one injec-
tion by itself mobilized similar numbers of HPCs in Fancc
 
 
 
/
 
 
 
and WT mice. Of interest is that the synergy in mobilization
of HPCs in Fancc
 
 
 
/
 
 
 
 mice was greater (P 
 
 
 
 0.001) than ef-
fects seen in WT mice. The reasons for this enhanced syn-
ergy in Fancc
 
 
 
/
 
 
 
 mice are not known. The results in Fig. 2
demonstrate that a single injection of AMD3100 greatly en-
hances G-CSF–induced mobilization.
 
AMD3100 effects on murine HSCs, without and with G-CSF
 
Although mobilization of HPC may be of use for short-term
repopulation in a transplant setting, HSCs are required for
long-term repopulation. To assess mobilization of murine
HSCs, we used a competitive repopulating assay (Fig. 3) in
which dilutions of donor blood cells that contain long-term re-
populating (LTR) cells compete with recipient marrow cells
for engraftment in lethally-irradiated recipients (36, 37). Donor
chimerism was assessed using CD45 congenic mice in which
donor cells were C57Bl/6 (CD45.2
 
 
 
) and recipients were
B6.BoyJ (CD45.1
 
 
 
). Cells mobilized by AMD3100 contained
LTR activity (Fig. 3 A, left). At 2–4 mo posttransplant, 3:1 and
2:1 ratios of AMD3100-mobilized donor/recipient competitor
cells sustained a greater than eight-fold higher chimerism com-
pared with cells that were mobilized from control medium–
treated donor mice; a 1:1 ratio of cells still produced signifi-
cantly enhanced engraftment of AMD3100-mobilized cells.
To test self-renewal of AMD3100-mobilized LTR cells, mar-
row cells that were obtained from competitively engrafted
mice at 4 mo posttransplantation with a 3:1 ratio of donor/re-
cipient cells were injected into lethally-irradiated secondary
mice in a noncompetitive assay (Fig. 3 A, right). All secondary
mice survived and 
 
 
 
50% of hematopoietic cells that engrafted
the secondary mice from cells of primary mice that received
cells that were mobilized with AMD3100 were of donor ori-
gin. Thus, AMD3100 rapidly mobilized LTR, self-renewing
mouse HSCs.
The combined effects of AMD3100 and G-CSF on
C57Bl/6 mice were assessed on mobilization of LTR cells.
As shown in Fig. 3 B (left panel), AMD3100 or G-CSF (two
times per day for 2 d) induced essentially equal mobilization
of long-term marrow competitive repopulatory (LTMCR)–
HSCs (see 1.5:1 donor/competitor ratio data). The combina-
tion of AMD3100 plus G-CSF was synergistic; effects were
seen most clearly with 1:1 donor/competitor cells, whereas
no increase in chimerism was seen with only AMD3100 or
G-CSF, but significant increases were seen with AMD3100
plus G-CSF. 6 mo after the transplants, cells were removed
from the marrows of competitively engrafted mice and in-
jected into lethally irradiated secondary recipient mice in a
noncompetitive assay (Fig. 3 B, right). CD45.2 donor cell
engraftment (
 
 
 
60%) of the secondary mice was apparent 6
mo after the secondary transplant for cells that initially were
mobilized with AMD3100 alone or in combination with
G-CSF. In the context of what is likely a suboptimal schedule
of G-CSF (2 d of G-CSF), AMD3100 enhances mobilization
of a LTMCR-HSC with self-renewal capacity.
 
AMD3100 effects on human HPCs and SRC, with and 
without G-CSF
 
Studies in Fig. 1 led, in part, to the first clinical evaluations
of AMD3100 for mobilization of CD34
 
 
 
 cells and HPCs in 
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healthy human volunteers (31, 32); studies in Fig. 2 led to
the first clinical evaluation of the combination of G-CSF and
AMD3100 for mobilization of CD34
 
 
 
 cells in healthy do-
nors (34). Peak mobilization of CFU-GM, BFU-E, and
CFU-GEMM occurred in humans 6 h after i.v. injection of
AMD3100. We tested whether AMD3100 could be admin-
Figure 3. AMD3100 mobilizes competitive repopulating mouse HSCs 
with self-renewal capacity (A) and G-CSF synergizes this effect (B). 
(A, left) 18 C57Bl/6 mice (CD45.2) serving as donors were injected s.c. with 
0.1 ml saline, and 36 C57Bl/6 mice were injected with 0.1 ml AMD3100 at 
5 mg/kg (  100  g/mouse). Blood was collected 1 h later and LDMNCs 
isolated. BM from nonirradiated B6.BoyJ (CD45.1) mice served as competitor 
cells. The ratio of donor (CD45.2) blood cells to competitor (CD45.1) BM cells 
was set as the number of LDMNC blood cells in 3 donor mice to a constant 
number of 0.5   106 competitor BM cells equaling 3:1. A 2:1 ratio was the 
number of LDMNCs in blood of 2 donor mice to 0.5   106 competitor cells, 
and a 1:1 ratio was LDMNC in 1 donor mouse to 0.5   106 competitor cells. 
Results are based on analysis of transplantation of 6 lethally irradiated 
recipients per test group of i.v. infused cells. Right panel: BM cells were 
removed from femurs of primary mice 4 mo after injection of 3:1 saline 
or 3:1 AMD3100:competitor cell mixture and 2.5   106 marrow cells from 
3 mice of each group injected separately into 3 lethally secondary irradiated 
B6.BoyJ mice in a noncompetitive assay. Results are shown as percent 
CD45.2 C57Bl/6 donor cell chimerism in CD45.1 B6.BoyJ recipients. *P   0.05; 
**P   0.01; ***P   0.001 compared with group 1 at each time point. (B) G-CSF 
and AMD3100 were administered as in Figure 2, part A, with G-CSF given 
twice a day for 2 d. Left panel: competitive repopulation in primary recipi-
ents 6 mo post transplant. The results are an average of mouse cells from 
five donors into six recipients each. Right panel: secondary repopulation in 
a noncompetitive assay 6 mo after transplant. Results are an average of 
3 donor mice with cells transplanted into three recipients each. *P   0.01 or 
**P   0.001 compared with control. 
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Figure 4. Influence of AMD3100, alone and with G-CSF, on cir-
culating HPCs in healthy human volunteers. (A) Influence of multiple 
injections of AMD3100 alone. Three volunteers were injected i.v. with 
AMD3100 (80  g/kg) on the first day (day 1) and again at 24 h. Progenitors/ml 
blood were assessed preinjection (day 1, 0 h) and at the noted time 
intervals. Fold changes are calculated based on the following day 1, 0 h 
progenitors/ml for three donors: CFU-GM (387, 78, 201), BFU-E (712, 78, 
217), and CFU-GEMM (77, 29, 93) grown in methylcellulose cultures in 
the presence of Epo, stem cell factor, and interleukin-3. The fold changes 
for CFU-GM also include progenitor cells/ml as calculated in agar culture 
medium with GM-CSF and stem cell factor (control numbers for three 
donors: 108, 18, 54). *P   0.001 compared with 0 h counts of that 
particular day. (B) Influence of AMD3100 on mobilization of circulating 
HPCs in healthy human volunteers receiving G-CSF or G-CSF plus 
AMD3100 (160  g/kg). The results shown are the mean plus range of 
fold increases of the absolute numbers of CFU-GM and CFU-GEMM per 
ml of blood for two healthy volunteers each without apheresis. Fold 
changes are based on the following numbers of G-CSF day 5, 0 h control 
progenitor cells/ml: group I: G-CSF (CFU-GM: 34403 and 27194; CFU-
GEMM: 14363 and 10083); group II: G-CSF (4 d) plus AMD3100 (day 5; 
CFU-GM: 11968 and 2675; CFU-GEMM: 3366 and 510), and group III: 
G-CSF (5 d) plus AMD3100 (day 5; CFU-GM: 2698 and 2380; CFU-GEMM: 
1028 and 1238). (C) Results of apheresis after mobilization of circulating 
HPCs. Results are expressed as total progenitors collected (in thousands) 
for donors receiving G-CSF (n   3), G-CSF   AMD3100 (160  g/kg; n   3), 
or AMD3100 (240  g/kg; n   4). *P   0.01 for G-CSF– or AMD3100 
versus G-CSF   AMD3100-mobilized cells. (D) Results of apheresis shown 
in C but expressed as progenitors mobilized per kg donor. *P   0.05 for 
same comparisons as in C. 
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istered to humans over two successive days, 24 h apart, and
still mobilize HPCs. Results shown in Fig. 4 A demonstrate
significant mobilization of HPCs within 6 h of each injec-
tion of AMD3100 given once a day on day 1, and days 1 and
2. The repetitive AMD3100 mobilizing capacity for human
HPCs is similar to that for mouse HPCs (Fig. 1 C).
To test the mobilizing effects of G-CSF plus AMD3100,
healthy volunteers received 4 d of G-CSF (10 
 
 
 
g/kg/d s.c. 
 
 
 
1) and then were randomized into three groups of two
donors each. One group was randomized to receive the
same amount of G-CSF on day 5, the second group received
only AMD3100 (160 
 
 
 
g/kg s.c. 
 
 
 
 1) on day 5, and the
third group received G-CSF and AMD3100 on day 5. HPC
numbers per milliliter were evaluated just before the last
treatment on day 5 of G-CSF, AMD3100, or the combina-
tion of G-CSF plus AMD3100, and also 1–48 h after the last
treatment. Peak fold change in numbers of CFU-GM and
CFU-GEMM per milliliter of blood occurred at 6 h (Fig. 4
B), when AMD3100 was given on day 5 after 4 d of G-CSF
administration and resulted in a greater than fourfold in-
crease in HPCs compared with 5 d of administration of
G-CSF. No further increase was seen when G-CSF was given
for 5 d with the addition of AMD3100 on the fifth day.
These results are comparable to the enhanced mobilization
of CD34
 
 
 
 cells that is seen with AMD3100 and G-CSF (34).
Thus, the combination of AMD3100 with G-CSF greatly
enhances mobilization of human HPCs, effects which are
similar to murine HPCs.
In further experiments, normal donors whose HPCs
were mobilized by multiple injections of G-CSF, or one in-
jection of AMD3100 (160 
 
 
 
g/kg) after multiple injections
of G-CSF as noted directly above, were apheresed (34). To-
tal numbers of HPCs apheresed and progenitors/kg donor
after apheresis are shown in Fig. 4 (C and D, respectively).
Unfortunately, we did not have access to samples from do-
nors who were mobilized by only 160 
 
 
 
g AMD3100/kg.
However, we compared these results with apheresis samples
from donors who were mobilized with one injection of 240
 
 
 
g AMD3100/kg. Mobilization of CD34
 
 
 
 cells with 240
 
 
 
g AMD3100/kg is equal to or slightly better than with a
160 
 
 
 
g/kg dose (31). As seen in Fig. 4 C and D, significantly
enhanced numbers of HPCs were seen in apheresed samples
from donors who were mobilized with the combination of
G-CSF plus AMD3100 compared with either G-CSF or
AMD3100 (higher dose than used with G-CSF), these ef-
fects were greater than additive, data were similar to mobili-
zation of CD34
 
 
 
 cells (34).
To evaluate mobilization of HSCs in humans, we used
the SRC assay (38, 39). We first compared numbers of
SRCs per 10
 
6
 
 CD34
 
 
 
 cells obtained after administration of
10 
 
 
 
g/kg G-CSF once a day for 5 d compared with that
mobilized 6 h after a single injection of 80 
 
 
 
g/kg AMD3100
(without G-CSF). The frequency of SRCs per 10
 
6
 
 CD34 
cells for four donors who were mobilized as in Fig. 4 (C and
D) by 5 d of G-CSF was 3.35   2.04 compared with 12.68  
6.36 for four donors who were mobilized by one injection
of 80  g/kg AMD3100. In four experiments, in which a
different G-CSF–mobilized sample was compared with each
AMD3100-mobilized sample, the increase in frequency of
SRCs per 106 CD34  cells for AMD3100- compared with
G-CSF–mobilized blood was 4.5   3.4-fold. We then com-
pared numbers of SRCs from apheresed blood of donors
who were mobilized by 5 d of G-CSF; 5 d of G-CSF plus
one injection of 160  g/kg AMD3100; or one injection of
240  g/kg AMD3100. The greatest number of SRCs/kg
were found in the group that was mobilized by the combi-
nation of G-CSF plus AMD3100 (Fig. 5 A). Human cell
chimerism in NOD/severe combined immunodeficiency
(SCID)  mice that received cells that were mobilized by
AMD3100 plus G-CSF was higher than with G-CSF; effects
were more apparent with limiting numbers of cells (2.0 vs.
0.3% chimerism at 75,000 cells and 3.0% vs. 1.5% at 150,000
cells, respectively, for G-CSF plus AMD3100 compared
with G-CSF alone; n   11–16 mice). Human cell chimer-
ism information was not available for AMD3100 alone.
Antigen expression and chemotaxis of human CD34  cells
Adhesion molecules and chemotactic responsiveness to
SDF-1/CXCL12 have been implicated in HSC/HPC hom-
ing (9). We examined expression of CD49d very late antigen
(VLA)-4, CD49e (VLA-5), CD62L (L-selectin), and CXCR4
on CD34  cells (Fig. 5 B) as percentage of positive cells (Fig.
5 B, i) and expression levels (Fig. 5 B, ii), and the chemotac-
tic response of these cells to SDF-1/CXCL12 (Fig. 5 C).
The percentage of CD34  cells that expressed CD62L (Fig.
5 B, i) and the level of CD62L expression (Fig. 5 B, ii) was
significantly lower in the G-CSF plus AMD3100-mobilized
cells compared with G-CSF-mobilized cells. There was a
trend toward a higher percentage for CD49e-expressing cells
(Fig. 5 B, i), but the expression level of CD49e on the dual
mobilized positive cells was significantly higher (Fig. 5 B, ii).
This mirrors the phenotype of highly engrafting murine BM
cells (40). No significant differences were apparent in ex-
pression of CD49d or CXCR4 on the differently mobilized
CD34 , cells although there was a trend to a higher percent-
age of CXCR4  cells (Fig. 5 B, i and ii). Percent positive
G-CSF–mobilized CD34  cells were similar to that of CD34 
human BM cells, although the expression levels of CD49d
and CXCR4 on BM was greater than that on G-CSF–
mobilized cells.
CD34  cells that were mobilized by AMD3100 plus
G-CSF were more responsive to the in vitro migratory ef-
fects of SDF-1/CXCL12 than those that were mobilized by
only G-CSF (Fig. 5 C). The combination of AMD3100 plus
G-CSF induces mobilization of more CD34  cells than
G-CSF or AMD3100 alone (34). However, the chemotaxis
data opened up the possibility that the enhanced numbers of
SRC cells that were mobilized by the combination of
G-CSF plus AMD3100 was due, in part, to enhanced hom-
ing of the G-CSF plus AMD3100-mobilized CD34  cells.AMD3100 MOBILIZATION OF STEM AND PROGENITOR CELLS | Broxmeyer et al. 1314
Figure 5. Influence of AMD3100, G-CSF, and the combination 
of G-CSF plus AMD3100 on mobilization of NOD-SCID SRCs from 
normal human volunteers (apheresis samples), surface expression 
of adhesion molecules and chemotaxis of CD34  cells, and hom-
ing of mobilized murine Sca1 Lin  cells. (A) SRCs per kg in aphere-
sis samples from G-CSF– (n   3), G-CSF   AMD3100- (160  g/kg; 
n   3), and AMD3100- (240  g/kg; n   4) mobilized circulating blood. 
Each set of test samples was assayed simultaneously in limiting dilu-
tions in conditioned NOD-SCID mice. For every sample, four different 
cell concentrations were used and four mice were transplanted with 
each cell concentration. Mice were assayed for chimerism 8 wk later; 
those that demonstrated  0.2% chimerism (total CD45  cells in BM) 
were considered to be positive. Percentage of negative mice were used 
to calculate SRC frequencies. (B, i) Expression of CD49d (VLA-4), CD49e 
(VLA-5), CD26L (L-selectin), and CXCR4 on mobilized CD34  cells (mean   
1SEM of percent positive cells of five to seven different G-CSF samples, 
three AMD3100 plus G-CSF samples, and four BM samples). (B, ii) Mean 
fluorescent intensity (MFI) of positive samples. Same number of samples 
evaluated as in B, i except G-CSF group has a different number (n  7). 
(C) CD34  cells isolated from G-CSF (n   6) and G-CSF plus AMD3100 
(n   3) mobilized peripheral blood were assessed for chemotaxis to 
SDF-1/CXCL12 (100 ng/ml) and results expressed as percentage of 
migrated cells. Data for each sample were collected in duplicate. 
(D, i) Homing of CD45.2  Sca1 Lin  BM cells from C57Bl/6 mice into 
lethally irradiated CD45.1  B6.BoyJ BM from samples mobilized with G-CSF 
(2 times/d for 4 d as in Fig. 2B; n   3), G-CSF   AMD3100 (5 mg/kg; 
n   4), and AMD3100 (5 mg/kg; n   3). Homing was assessed as in 
Materials and methods. (D, ii) Competitive repopulation of CD45.2  BM 
cells recovered after homing shown in D, i. Results of chimerism are 
after 4 mo in 2  irradiated B6.BoyJ recipients. For A–D, significant 
differences compared with G-CSF: *P   0.001; **P   0.01; ***P   0.05; 
all other values are P   0.05. NA, data not depicted.JEM VOL. 201, April 18, 2005 1315
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Homing of human CD34  cells (77–87% pure) that were
collected from apheresed samples of two mice each after
mobilization with G-CSF, G-CSF   AMD3100 (160  g/
kg), and AMD3100 was assessed in conditioned NOD/
SCID BM after 20 h. No significant difference was noted in
recovery of human CD34  cells (1.5   0.2%, 1.2   1.0%,
and 1.8   0.2%, respectively) for the three groups. Because
the percentage of human homed cells was low, and the re-
sults were based on phenotype only, we also assessed the
homing of mobilized murine Sca Lin  cells (C57Bl/6) into
lethally irradiated B6.BoyJ mice (Fig. 5 D). There was signif-
icantly decreased homing of G-CSF plus AMD3100-mobi-
lized cells compared with those that were mobilized with
only G-CSF (Fig. 5 D, i). When these phenotypically
homed cells were analyzed for competitively repopulating
capacity to prove that the phenotyped cells contained stem
cells, the competitive repopulating ability of the G-CSF plus
AMD3100-mobilized cells was similar to that of G-CSF–
mobilized cells (Fig. 5 D, ii). Numbers of Sca1 c-kit Lin 
cells/ml blood that were mobilized by the combination of
G-CSF plus AMD3100 demonstrated an approximately
threefold increase compared with those mobilized only by
G-CSF. Numbers of Sca1 c-kit Lin  cells (in thousands)
per ml for G-CSF plus AMD3100 compared with G-CSF
were 31.4   10.9 and 10.1   3.4, respectively (P   0.01).
Thus, we could not link enhanced numbers of SRCs/HSCs
that were mobilized by G-CSF plus AMD3100 to enhanced
homing of G-CSF plus AMD3100-mobilized cells.
DISCUSSION
Stem cell transplantation is curative for many life-threatening
disorders. The first source of transplantable HSCs was BM
(41). Subsequently, mobilized peripheral blood (7, 8) and
cord blood (6) were found to contain HSCs. By the 1990s,
the majority of autologous and allogeneic HSC transplants
following myeloablative therapy in patients who had hema-
tolymphoid malignancies or solid tumors were done with
cytokine-mobilized HSCs; G-CSF was the most frequently
used inducer of HSC/HPC mobilization (7, 8). However,
there is large individual variability in responsiveness of nor-
mal donors and patients to the HSC/HPC-mobilizing ca-
pacity of G-CSF (7, 8, 10, 13, 42–45), and various cytokines
and other agents have been evaluated alone and in combina-
tion with G-CSF to enhance HSC/HPC mobilization.
One potential mechanism for retaining HSCs/HPCs in
the marrow is the attraction of CXCR4-expressing HSCs/
HPCs to marrow stromal cell–produced SDF-1/CXCL12
(16, 20), a possibility that was substantiated by additional ex-
perimental evidence (24–27). Thus, we postulated that
known specific antagonism of SDF-1/CXCL12 binding to
CXCR4 (28, 29) could be used clinically for mobilization
of HSCs/HPCs. That AMD3100 could mobilize human
CD34  HPCs was reported recently (31–33). The impetus
to pursue the clinical studies of AMD3100 as a mobilizer of
human CD34  cells and HPCs was, in large part, a conse-
quence of our initial studies that demonstrated that AMD3100
could mobilize HPCs rapidly in mice and synergized
with G-CSF to enhance this mobilization. These studies
are reported for the first time in Fig. 1 A–C and Fig. 2 A–C
respectively.
Although mobilization of HPCs and CD34  cells in re-
sponse to AMD3100 is of interest, proof that AMD3100 also
mobilizes HSCs is of paramount importance if AMD3100 is
to be a useful source of long-term engrafting cells. That
AMD3100 is a rapid mobilizer of murine HSCs and human
SRCs is seen in Figs. 3 and 5. Mouse data that are shown in
Fig. 3 are definitive proof that AMD3100 mobilizes a LTR
cell with self-renewal capacity.
Although expression of CD34 is considered clinically to
be a surrogate measure of stem cells, CD34  cells constitute
a relatively heterogenous group of cells, of which HPCs can
constitute 10–50% of the population, depending on how
pure the CD34  population is and the level of expression of
CD34 on the isolated cells. The HSC content of CD34 
cells is very small ( 1%), and not all HSCs that are inherent
within the CD34  population may be LTR cells. Thus, al-
though phenotypic markers are of some use, it is the func-
tional attributes of mobilized cells from donors that are of
greatest relevance and importance, especially when one con-
siders using these cells for clinical transplantation. The assay
that is best recognized as defining a functionally competent
human HSC involves human cell engraftment of sublethally
irradiated immune-deficient mice, such as NOD-SCID mice
(38, 39). Only an extremely small percentage of SRCs are
found in the population of CD34 CD38  human cells (46)
and this phenotype is a minor fraction of total CD34  cells.
It is apparent from our current studies that human SRCs are
mobilized by AMD3100, which suggests the importance of
the SDF-1/CXCL12-CXCR4 axis for retention of SRCs in
the human marrow microenvironment. If AMD3100 is to
be used by itself for clinical mobilization, the data shown in
Fig. 1 C (for murine HPCs) and in Fig. 4 A (for human
HPCs) are of relevance because they demonstrate that num-
bers of mobilized cells can be increased by consecutive col-
lections after repeated injections of AMD3100.
The combined use of G-CSF and AMD3100 may have
the greatest clinical impact, and our recent study has demon-
strated that G-CSF plus AMD3100 mobilizes greater
numbers of CD34  cells/kg donor body weight than ei-
ther G-CSF or AMD3100 (34). That a single injection of
AMD3100 synergized with multiple additions of G-CSF for
HPCs and LTMCR- and self-renewing–HSCs in mice and
for HPCs and SRCs in man suggests that the mechanisms
that are inherent in G-CSF and AMD3100 mobilization of
HSCs and HPCs are likely different, or do not overlap com-
pletely. Extensive efforts have gone into understanding the
interacting elements that are involved in the mobilization of
HSCs and HPCs, including that of the SDF-1/CXCL12-
CXCR4 axis (9). Adhesion molecules have been implicated
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(9). It is of interest that the expression profile of the dual
AMD3100/G-CSF–mobilized CD34  human cells (Fig. 5
B) mirrors the phenotype of highly engrafting murine BM
cells (40). The functional and mechanistic relevance of this
murine HSC and human CD34  phenotype remains to be
determined. It did not seem that enhanced engrafting capa-
bility of the G-CSF plus AMD3100-mobilized cells was due
to enhanced homing of these cells (Fig. 5 D, i and ii) within
the context of the specific timing and experimental proce-
dure that we used. However, more intricate homing studies
that can determine exactly where homed cells arrive in the
microenvironmental niche are needed to answer definitively
whether homing played a role. Unfortunately, this technol-
ogy is not yet available. The highly engrafting nature of the
dual mobilized cells makes it clear that the AMD3100 mobi-
lization process does not interfere with the functional capac-
ity of the mobilized cells; this is consistent with the antago-
nistic and rapidly reversible effects of AMD3100 (28, 29).
Efforts are moving quickly to evaluate cells that are mo-
bilized by the combination of G-CSF and AMD3100 in a
clinical setting. The side effects of single-dose administration
of AMD3100 to normal donors are very minor (31–34).
AMD3100 does not cause bone pain when administered
alone, or increase G-CSF–related bone pain when given in
combination with G-CSF. The results presented here sug-
gest that dual AMD3100/G-CSF, and AMD3100 alone,
mobilize high-quality populations of HSCs that should pro-
vide stable long-term hematopoietic engraftment.
MATERIALS AND METHODS
Cells
Peripheral blood was obtained from C57Bl/6, DBA/2, and C3H/HeJ mice
that were purchased from Harlan Laboratories or Jackson ImmunoResearch
Laboratories. Congenic C57Bl/6 (CD45.2 ) and B6.SJL-Ptrca Pep3b/BoyJ
(B6.BoyJ:CD45.1) mice were purchased from Jackson ImmunoResearch
Laboratories. Fancc    and  /  (WT) mice originally were obtained from M.
Buchwald (Hospital for Sick Children and University of Toronto, Toronto,
Ontario, Canada) (47). NOD-SCID mice were purchased from Jackson Im-
munoResearch Laboratories. The Institutional Animal Care and Use Com-
mittee of the Indiana University School of Medicine approved all experimen-
tal procedures with the mice used. Mice were bred and/or maintained at the
animal facilities of the Indiana University School of Medicine. Blood cells
from healthy human volunteers (ages 24–33 yr) were obtained following pro-
tocols approved by the Human Subjects Committee/Institutional Review
Boards of the University of Washington, Indiana University School of Medi-
cine, and the Scientific Advisory Committee for the Clinical Research Cen-
ter of the University of Washington Medical Center. Informed consent was
obtained from all volunteers before enrollment in study protocols. All sub-
jects had normal blood cell counts, normal liver and kidney functions, were
normal on physical examination, and were not taking regular medication.
Normal electrocardiogram findings were required (31, 32, 34). Each subject
was admitted to the Clinical Research Center for injections of AMD3100
(AnorMed, Inc.), blood sampling, and clinical observation. Human BM also
was obtained with Institutional Review Board approval and informed con-
sent at Indiana University. LDMNCs were obtained from mouse and human
blood/BM by density cut procedures using murine lympholyte and Ficoll
Hypaque (Amersham Biosciences), respectively. Human CD34  cells were
isolated first into a LDMNC fraction and then purified by positive selection
with a Magnetic Affinity Cell Separation CD34  isolation kit (Miltenyi Bio-
tec; purity of isolated cells was  90% CD34  unless otherwise noted).
HPC assays
Mouse and human cells were assayed for CFU-GM, BFU-E, and CFU-
GEMM using ingredients and cytokine combinations as noted elsewhere (3,
22, 23). For mouse HPCs, cells were cultured in 1% methylcellulose with
30% FBS (Hyclone) with 1 U/ml rhu Epo, 5% (vol/vol)) pokeweed mito-
gen mouse spleen cell conditioned medium, and 50 ng/ml recombinant
murine stem cell factor (  steel factor). For human HPCs, we used methyl-
cellulose, 30% FBS, 1 U/ml rhu Epo, 10 ng/ml rhu GM-CSF, 10 ng/ml
rhu IL-3, and 50 ng/ml rhu stem cell factor. Colonies were scored after 14
d for human cells and after 7 d for mouse cells in a humidified atmosphere
with 5% CO2 and lowered (5%) O2. Cytokines were purchased from R&D
Systems, except for Epo which was purchased from Amgen Corp.
Pokeweed mitogen mouse spleen cell conditioned medium was prepared as
described previously (3).
Mouse HSC and human SRC assays
The mouse LTR cell assay detects functional and competitive stem cells
(36). The LTR cell assay and phenotyping for donor (CD45.2 ) and recip-
ient (CD45.1 ) cells was performed as previously described (23, 37), and as
noted in the legend to Fig. 3. Recipient mice were given a lethal dose of ir-
radiation (950 cGy) before i.v. injection of cells. Additionally, BM cells re-
covered from lethally irradiated mice repopulated by donor cells were in-
jected i.v. into lethally irradiated secondary mice without the injection of
competitor cells as noted in the legend to Fig. 3.
The human SRC assay was performed in sublethally irradiated (300
cGy) NOD-SCID mice as described previously (48), using limiting dilution
analysis (49).
Flow cytometry and chemotaxis assay
Quantitation of surface antigens was performed in the Flow Cytometry
Core Facility of the Indiana University School of Medicine and the Na-
tional Cancer Institute–Designated Indiana University Cancer Center.
FITC-conjugated anti–mouse CD45.2 and anti–mouse C45.1 (BD Bio-
sciences) was used to assay mouse donor cell chimerism of transplanted
B6.BoyJ mice (23), whereas anti–human CD45 (FITC, clone 2D1; BD
PharMingen) was used to assess human donor cell chimerism of NOD-
SCID mice (45). CD34 (PE, clone 8G12), CD49e (PE, clone 11A1),
CD62L (FITC, clone Dreg56), and CXCR4 (PE, clone 12G5) antibodies
were purchased from BD Biosciences. CD49d (FITC, clone HP2/1) anti-
body was purchased from Coulter-Immunotech. Chemotaxis assay was
done as described previously (50) using SDF-1/CXCL12 that was pur-
chased from R&D Systems.
Methods for stem cell homing studies
Fresh cells. A known volume of mobilized peripheral blood was obtained
from 10 C57Bl/6 mice/group. Low density cells were obtained, enumer-
ated, and phenotyped by flow cytometry using biotinylated Sca-1 devel-
oped with SA-PerCPCy5.5, lineage markers conjugated to APC (CD3,
B220, Gr-1), and cKit-FITC. Cells were analyzed using a FACSCaliber
(Becton Dickinson), and all antibodies were obtained from BD Biosciences.
Homing studies. Low-density mobilized peripheral blood PB from 10
C57Bl/6 donor mice/group was pooled and 40   106 cells were trans-
planted via tail vein injections into one to four B6.BoyJ recipients/group
(10 wk old). Mice were killed 11 h later, BM isolated, red cells lysed, and
cells phenotyped by flow cytometry using CD45.2-FITC, biotinylated
Sca-1 developed with SA-PerCPCy5.5, and lineage markers conjugated to
APCs (CD3, B220, Gr-1). Recovery of primitive BM-homed donor cells
was calculated as described previously (51, 52). Frequency of donor cells,
and Sca-1 Lin  cells—falling within a light scatter gate, including lympho-
cytes and large granular cells—was determined for each mouse. Frequencies
were multiplied by the total number of cells in each tissue, then divided by
the number of cells in the original graft to calculate the recovery of trans-
planted cells. Numbers of BM cells that were harvested from tibias and fe-
murs were considered to represent 18.7% of total murine marrow (53).JEM VOL. 201, April 18, 2005 1317
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Transplantation studies. A fraction of BM-homed donor cells from the
primary B6.BoyJ recipients was assessed for long-term competitive repopulat-
ing potential in lethally-irradiated secondary B6.BoyJ recipients (51, 52). A
volume of marrow from one primary mouse that contained 3   105 donor
C57Bl/6 cells was transplanted along with 105 competitor low density bone
marrow of B6.BoyJ origin into one B6.BoyJ recipient within 2–3 h of re-
ceiving lethal irradiation in a split dose of 650cGy   300cGy, 4 h apart. Mice
were bled from the tail vein monthly for analysis of donor-derived hemato-
poiesis by determining the percentage of CD45.2 CD45.1  PB leucocytes.
Human to NOD/SCID homing. Homing of CD34  cells was assessed
as described (54). In brief, test samples, with a known percentage of CD34 
cells were transplanted i.v. into 10–12-wk-old NOD/SCID mice condi-
tioned with 300 cGy total body irradiation to deliver 2.5   106 CD34 
cells per mouse. Approximately 20 h later, BM cells were collected and the
percentage of human cells was determined by direct measurement of total
human CD45  cells.
Statistical analysis
Results are expressed as mean   1 SD unless otherwise noted. Statistical
differences between groups was determined for in vitro colony forming cell
(HPC) studies using Student’s t test. An unpaired two-sided Student’s t test
was used to evaluate significant differences in chimerism for in vivo trans-
plantation studies.
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